Open AccessFirst clinical experience of the use of ustekinumab (Stelara) for treatment of psoriatic patients in Russia
Author(s) -
L. F. Znamenskaya,
Svetlana I. Svishchenko
Publication year - 2012
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv667
Subject(s) - ustekinumab , medicine , psoriasis , interleukin 23 , dermatology , psoriasis area and severity index , clinical efficacy , interleukin , disease , cytokine , infliximab
The authors examined the efficacy and safety of treatment of patients suffering from moderate to severe forms of psoriasis with ustekinumab (blocker of р40 subunit of interleukin-12 and interleukin-23) taking into account the PASi index. They revealed high clinical efficacy of ustekinumab for treatment of psoriatic patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom